Mariona Pinart1, Jennifer Kranz2, Katrin Jensen3, Tanja Proctor3, Kurt Naber4, Frank Kunath5, Florian Wagenlehner6, Stefanie Schmidt7. 1. UroEvidence@Deutsche Gesellschaft für Urologie, Nestorstraße 8/9 (1. Hof), 10709 Berlin, Germany. 2. Department of Urology and Pediatric Urology, St. Antonius Hospital, Eschweiler, Germany. 3. Institute of Medical Biometry and Informatics, University Heidelberg, Heidelberg, Germany. 4. Technical University of Munich, Munich, Germany. 5. UroEvidence@Deutsche Gesellschaft für Urologie, Nestorstraße 8/9 (1. Hof), 10709 Berlin, Germany; Department of Urology, University Hospital Erlangen, Erlangen, Germany. 6. Department of Urology, Pediatric Urology and Andrology, Justus-Liebig University, Gießen, Germany. 7. UroEvidence@Deutsche Gesellschaft für Urologie, Nestorstraße 8/9 (1. Hof), 10709 Berlin, Germany. Electronic address: schmidt@dgu.de.
Abstract
OBJECTIVE: To compare the efficacy and safety of different pivmecillinam (PIV) regimes for uncomplicated lower urinary tract infections (UTIs). METHODS: The MEDLINE, Embase, and Cochrane Library databases were searched. Randomized controlled clinical trials (RCTs) involving adults or children with symptoms suggestive of uncomplicated UTI and that compared different PIV regimes or PIV versus other antibiotics were included. Meta-analyses were conducted to obtain direct and indirect efficacy estimates. PIV regimes were categorized into high total dosage, moderate total dosage, and low total dosage. The risk of bias was evaluated using the Cochrane tool. RESULTS: Twenty-four RCTs were identified. No difference in clinical cure was found for the high vs. moderate (short-term: risk ratio (RR) 1.01, p=0.813; long term: RR 1.09, p=0.174) or high vs. low dosage comparisons (mean difference 0, 95% confidence interval -0.44 to 0.45, p=1). For bacteriological cure, comparisons of high vs. moderate dosage (short term: RR 1.05, p=0.056; long term: RR 1.05, p=0.131) and high vs. low dosage (short term: RR 1.02, p=0.759; long term: RR 1.13, p=0.247) showed a trend in favor of the high dosage treatment. Results for relapse, re-infection, and failure were inconclusive and not statistically significant. Patients treated with high dosages were 40% (p=0.062) and 44% (p=0.293) more likely to report mild to moderate adverse events. CONCLUSIONS: There is insufficient evidence to support the use of an optimal combination of dosage, frequency, and duration of PIV therapy for the treatment of uncomplicated lower UTI. Evidence is limited due to the high risk of bias, poor reporting, and heterogeneous study data.
OBJECTIVE: To compare the efficacy and safety of different pivmecillinam (PIV) regimes for uncomplicated lower urinary tract infections (UTIs). METHODS: The MEDLINE, Embase, and Cochrane Library databases were searched. Randomized controlled clinical trials (RCTs) involving adults or children with symptoms suggestive of uncomplicated UTI and that compared different PIV regimes or PIV versus other antibiotics were included. Meta-analyses were conducted to obtain direct and indirect efficacy estimates. PIV regimes were categorized into high total dosage, moderate total dosage, and low total dosage. The risk of bias was evaluated using the Cochrane tool. RESULTS: Twenty-four RCTs were identified. No difference in clinical cure was found for the high vs. moderate (short-term: risk ratio (RR) 1.01, p=0.813; long term: RR 1.09, p=0.174) or high vs. low dosage comparisons (mean difference 0, 95% confidence interval -0.44 to 0.45, p=1). For bacteriological cure, comparisons of high vs. moderate dosage (short term: RR 1.05, p=0.056; long term: RR 1.05, p=0.131) and high vs. low dosage (short term: RR 1.02, p=0.759; long term: RR 1.13, p=0.247) showed a trend in favor of the high dosage treatment. Results for relapse, re-infection, and failure were inconclusive and not statistically significant. Patients treated with high dosages were 40% (p=0.062) and 44% (p=0.293) more likely to report mild to moderate adverse events. CONCLUSIONS: There is insufficient evidence to support the use of an optimal combination of dosage, frequency, and duration of PIV therapy for the treatment of uncomplicated lower UTI. Evidence is limited due to the high risk of bias, poor reporting, and heterogeneous study data.
Authors: Sinead Duane; Claire Beecher; Akke Vellinga; Andrew W Murphy; Martin Cormican; Andrew Smyth; Patricia Healy; Michael Moore; Paul Little; Declan Devane Journal: JAC Antimicrob Resist Date: 2022-03-22
Authors: Filip Jansåker; Sara Thønnings; Frederik Boëtius Hertz; Thomas Kallemose; Jan Værnet; Lars Bjerrum; Thomas Benfield; Niels Frimodt-Møller; Jenny Dahl Knudsen Journal: EClinicalMedicine Date: 2019-07-20
Authors: Ana Garcia-Sangenís; Rosa Morros; Mercedes Aguilar-Sánchez; Laura Medina-Perucha; Alfonso Leiva; Joana Ripoll; Mar Martínez-Pecharromán; Cruz B Bartolomé-Moreno; Rosa Magallon Botaya; Jaime Marín-Cañada; José M Molero; Ana Moragas; Amelia Troncoso; Ramon Monfà; Carl Llor Journal: BMJ Open Date: 2021-11-25 Impact factor: 2.692
Authors: Cheol In Kang; Jieun Kim; Dae Won Park; Baek Nam Kim; U Syn Ha; Seung Ju Lee; Jeong Kyun Yeo; Seung Ki Min; Heeyoung Lee; Seong Heon Wie Journal: Infect Chemother Date: 2018-03